Treatment of Hepatitis C Infections with Interferon: A Historical Perspective

Interferons were first described in 1957, but it was not until 34 years after their discovery that sufficient quantities of it were available for treatment of hepatitis C virus (HCV) infections, Clinicians now have an excellent understanding of the basis for the effectiveness of interferon alpha (IF...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedman, Robert M., Contente, Sara
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2989738/
https://www.ncbi.nlm.nih.gov/pubmed/21152181
http://dx.doi.org/10.1155/2010/323926
_version_ 1782192387521511424
author Friedman, Robert M.
Contente, Sara
author_facet Friedman, Robert M.
Contente, Sara
author_sort Friedman, Robert M.
collection PubMed
description Interferons were first described in 1957, but it was not until 34 years after their discovery that sufficient quantities of it were available for treatment of hepatitis C virus (HCV) infections, Clinicians now have an excellent understanding of the basis for the effectiveness of interferon alpha (IFN-α) in the therapy of this disease. Treatment with IFN-α is more efficient when it complemented by the antiviral ribavirin and the IFN-α is conjugated with polyethylene glycol to form peginterferon. In the near future treatment of HCV with IFN-α may involve new anti-HCV agents that are currently under development.
format Text
id pubmed-2989738
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-29897382010-12-09 Treatment of Hepatitis C Infections with Interferon: A Historical Perspective Friedman, Robert M. Contente, Sara Hepat Res Treat Review Article Interferons were first described in 1957, but it was not until 34 years after their discovery that sufficient quantities of it were available for treatment of hepatitis C virus (HCV) infections, Clinicians now have an excellent understanding of the basis for the effectiveness of interferon alpha (IFN-α) in the therapy of this disease. Treatment with IFN-α is more efficient when it complemented by the antiviral ribavirin and the IFN-α is conjugated with polyethylene glycol to form peginterferon. In the near future treatment of HCV with IFN-α may involve new anti-HCV agents that are currently under development. Hindawi Publishing Corporation 2010 2010-09-06 /pmc/articles/PMC2989738/ /pubmed/21152181 http://dx.doi.org/10.1155/2010/323926 Text en Copyright © 2010 R. M. Friedman and S. Contente. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Friedman, Robert M.
Contente, Sara
Treatment of Hepatitis C Infections with Interferon: A Historical Perspective
title Treatment of Hepatitis C Infections with Interferon: A Historical Perspective
title_full Treatment of Hepatitis C Infections with Interferon: A Historical Perspective
title_fullStr Treatment of Hepatitis C Infections with Interferon: A Historical Perspective
title_full_unstemmed Treatment of Hepatitis C Infections with Interferon: A Historical Perspective
title_short Treatment of Hepatitis C Infections with Interferon: A Historical Perspective
title_sort treatment of hepatitis c infections with interferon: a historical perspective
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2989738/
https://www.ncbi.nlm.nih.gov/pubmed/21152181
http://dx.doi.org/10.1155/2010/323926
work_keys_str_mv AT friedmanrobertm treatmentofhepatitiscinfectionswithinterferonahistoricalperspective
AT contentesara treatmentofhepatitiscinfectionswithinterferonahistoricalperspective

Ejemplares similares